Loading…
Medical Disability Examination Improvement Act of 2025
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2025 · third_quarter · Alcohol and Drug Abuse
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
Read twice and referred to the Committee on Veterans' Affairs.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2025 · third_quarter · Health Issues
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2025 · third_quarter · Medical/Disease Research/Clinical Labs
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2025 · third_quarter · Medicare/Medicaid
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2025 · third_quarter · Budget/Appropriations
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2025 · third_quarter · Insurance
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)